B6.129P2(Cg)-Tnfrsf1atm3.3Gkl/Flmg

Status

Available to order

EMMA IDEM:11019
Citation informationRRID:IMSR_EM:11019 

Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information.

International strain nameB6.129P2(Cg)-Tnfrsf1atm3.3Gkl/Flmg
Alternative nameB6.129P2(Cg)-Tnfrsf1a/Flmg
Strain typeTargeted Mutant Strains : Knock-out
Allele/Transgene symbolTnfrsf1atm3.3Gkl
Gene/Transgene symbolTnfrsf1a

Information from provider

ProviderGeorge Kollias
Provider affiliationBSRC Fleming
Genetic informationAn FRT-flanked neomycin resistance cassette with a 5' loxP site was inserted upstream of exon 2. A second loxP site was inserted downstream of exon 5. Flp-mediated recombination removed the selection cassette and left exons 2 through 5 floxed. Cre-mediated recombination, specific to the myeloid lineage, removed exons 2 through 5.
Phenotypic informationHomozygous:
No overt phenotype

Heterozygous:
No overt phenotype
References
  • Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium.;Van Hauwermeiren Filip, Armaka Marietta, Karagianni Niki, Kranidioti Ksanthi, Vandenbroucke Roosmarijn E, Loges Sonja, Van Roy Maarten, Staelens Jan, Puimège Leen, Palagani Ajay, Berghe Wim Vanden, Victoratos Panayiotis, Carmeliet Peter, Libert Claude, Kollias George, ;2013;The Journal of clinical investigation;123;2590-603; 23676465
  • Opposing role of tumor necrosis factor receptor 1 signaling in T cell-mediated hepatitis and bacterial infection in mice.;Wroblewski Raluca, Armaka Marietta, Kondylis Vangelis, Pasparakis Manolis, Walczak Henning, Mittrücker Hans-Willi, Schramm Christoph, Lohse Ansgar W, Kollias George, Ehlken Hanno, ;2016;Hepatology (Baltimore, Md.);64;508-21; 26991125
Homozygous fertileyes
Homozygous viableyes
Homozygous matings requiredno
Immunocompromisedno

Information from EMMA

Archiving centreB.S.R.C. Alexander Fleming, Vari, Greece
Animals used for archivingheterozygous C57BL/6 males

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

    • Tumor necrosis factor receptor 1 associated periodic syndrome / Orphanet_32960
IMPC phenotypes (gene matching)
  • abnormal skin morphology / IMPC
  • increased large unstained cell number / IMPC
  • increased grip strength / IMPC
  • increased basophil cell number / IMPC
  • increased neutrophil cell number / IMPC
  • increased eosinophil cell number / IMPC
  • increased NK cell number / IMPC
  • abnormal cholesterol homeostasis / IMPC
  • decreased circulating calcium level / IMPC
  • increased lymphocyte cell number / IMPC
  • increased effector memory CD8-positive, alpha-beta T cell number / IMPC
  • increased circulating aspartate transaminase level / IMPC
  • enlarged heart / IMPC
  • increased leukocyte cell number / IMPC
  • decreased monocyte cell number / IMPC
  • abnormal heart morphology / IMPC
  • decreased neutrophil cell number / IMPC
MGI phenotypes (gene matching)
  • increased bone mineral density / MGI
  • abnormal Peyer's patch morphology / MGI
  • abnormal sleep pattern / MGI
  • abnormal immune system physiology / MGI
  • decreased IgG level / MGI
  • liver inflammation / MGI
  • lung inflammation / MGI
  • decreased inflammatory response / MGI
  • increased skin papilloma incidence / MGI
  • decreased tumor incidence / MGI
  • abnormal respiratory mechanics / MGI
  • abnormal airway responsiveness / MGI
  • abnormal lymph node B cell domain morphology / MGI
  • abnormal spleen germinal center morphology / MGI
  • abnormal Peyer's patch follicle morphology / MGI
  • decreased susceptibility to bacterial infection / MGI
  • increased susceptibility to bacterial infection / MGI
  • abnormal macrophage physiology / MGI
  • granulomatous inflammation / MGI
  • impaired skin barrier function / MGI
  • abnormal glutamate-mediated receptor currents / MGI
  • decreased circulating alanine transaminase level / MGI
  • abnormal cytokine secretion / MGI
  • no phenotypic analysis / MGI
  • abnormal nervous system physiology / MGI
  • abnormal response/metabolism to endogenous compounds / MGI
  • increased susceptibility to experimental autoimmune encephalomyelitis / MGI
  • decreased susceptibility to experimental autoimmune encephalomyelitis / MGI
  • decreased susceptibility to autoimmune diabetes / MGI
  • increased susceptibility to parasitic infection / MGI
  • increased susceptibility to type I hypersensitivity reaction / MGI
  • decreased Peyer's patch number / MGI
  • abnormal follicular dendritic cell morphology / MGI
  • absent follicular dendritic cells / MGI
  • decreased IgG1 level / MGI
  • increased circulating tumor necrosis factor level / MGI
  • decreased circulating interleukin-6 level / MGI
  • decreased circulating interleukin-1 beta level / MGI
  • increased interleukin-6 secretion / MGI
  • decreased interleukin-6 secretion / MGI
  • abnormal chemokine secretion / MGI
  • decreased susceptibility to endotoxin shock / MGI
  • increased susceptibility to endotoxin shock / MGI
  • decreased physiological sensitivity to xenobiotic / MGI
  • increased sensitivity to induced cell death / MGI
  • increased sensitivity to induced morbidity/mortality / MGI
  • decreased sensitivity to induced morbidity/mortality / MGI
  • decreased sensitivity to xenobiotic induced morbidity/mortality / MGI
  • increased susceptibility to bacterial infection induced morbidity/mortality / MGI
  • abnormal neuron proliferation / MGI
  • abnormal oval cell physiology / MGI
  • tumor regression / MGI
  • impaired adaptive thermogenesis / MGI
  • decreased susceptibility to dopaminergic neuron neurotoxicity / MGI
  • decreased microglial cell number / MGI
  • impaired humoral immune response / MGI
  • impaired central nervous system regeneration / MGI

Literature references

  • Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium.;Van Hauwermeiren Filip, Armaka Marietta, Karagianni Niki, Kranidioti Ksanthi, Vandenbroucke Roosmarijn E, Loges Sonja, Van Roy Maarten, Staelens Jan, Puimège Leen, Palagani Ajay, Berghe Wim Vanden, Victoratos Panayiotis, Carmeliet Peter, Libert Claude, Kollias George, ;2013;The Journal of clinical investigation;123;2590-603; 23676465
  • Opposing role of tumor necrosis factor receptor 1 signaling in T cell-mediated hepatitis and bacterial infection in mice.;Wroblewski Raluca, Armaka Marietta, Kondylis Vangelis, Pasparakis Manolis, Walczak Henning, Mittrücker Hans-Willi, Schramm Christoph, Lohse Ansgar W, Kollias George, Ehlken Hanno, ;2016;Hepatology (Baltimore, Md.);64;508-21; 26991125

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen sperm. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).